Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Bogang Wu et al.|Clinical Cancer Research|2024Cited by 43
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Sheng Sun et al.|Unknown|2024Cited by 1